Tumor-driven angiogenesis creates vessels that are irregular and leaky, rather than providing evenly distributed flow. This architecture produces uneven blood movement, so some regions receive less oxygen and nutrients while waste removal and therapeutic transport become inconsistent. In turn, this vascular disorder helps explain why treatment response can vary across different parts of the same tumor.
When blood flow is uneven, poorly supplied regions can become hypoxic, meaning oxygen availability is low. At the same time, elevated interstitial pressure makes it harder for therapeutic agents to move through tumor tissue. Considering both conditions helps bioengineers interpret limited penetration as a microenvironmental transport problem, not simply as a failure of the treatment itself.
Blood circulation through a tumor can vary because angiogenic vessels produce uneven flow across tissue. Consequently, oxygenation, nutrient supply, waste removal, and access for therapeutic agents may differ between regions or change as the tumor microenvironment changes. Treating perfusion as dynamic encourages measurements and models that capture spatial variation and treatment response instead of relying on a single uniform value.
Imaging provides a way to assess perfusion in tumor tissue by examining blood delivery and circulation. These measurements can help evaluate oxygenation-related conditions, identify unevenly supplied regions, and relate vascular behavior to treatment response. In bioengineering, imaging also complements engineered models, allowing researchers to compare observed vascular function with behavior reproduced in controlled experimental systems.
These models let researchers study vascular function under engineered conditions while examining how the tumor microenvironment shapes transport. Microfluidic and three-dimensional platforms can investigate drug penetration, reproduce relevant perfusion behavior, and evaluate treatment response in a controlled setting. Such systems support bioengineering strategies aimed at improving therapeutic delivery without depending only on measurements from tumors.
Perfusion measurements can connect vascular behavior with three practical outcomes: how far therapeutic agents penetrate, how a tumor responds to treatment, and whether delivery strategies improve access to poorly supplied tissue. They also reveal how the tumor microenvironment influences disease progression. This makes perfusion relevant to evaluating therapies and designing engineered approaches that address delivery limitations.